119-HR-5791 Journalist Public Summary

Headline Summary

A House bill would have the FDA fast‑track approvals so blood centers can add apheresis collection devices at new sites within 30 days, aiming to expand donation capacity while keeping safety checks in place.

What It Does

The BLOOD Centers Act directs the Department of Health and Human Services (through the FDA) to create an expedited process for supplements to existing biologics licenses when a blood center wants to add an apheresis collection device at a location not previously licensed. Under this process, FDA must approve the supplement within 30 days of submission unless it identifies a specific safety, purity, or potency concern at that location, or finds a broader, systemic failure by the operator. The fast‑track applies only to operators that already hold a blood‑center biologics license and either (a) have three or more FDA‑registered locations under that license, or (b) are accredited and in good standing by a qualifying blood‑collection accreditor.

Why It Matters

• Could make it faster to open or expand donation sites, potentially increasing availability of platelets and plasma collected by apheresis.
• Seeks to reduce administrative lag for experienced or accredited operators while preserving the ability for FDA to pause or deny if there are concrete safety issues.
• Intended to help communities scale up donation capacity during routine operations or local surges.

Who’s For It

• Bill sponsors: Reps. Tony Wied, Kim Schrier, and Tom Tiffany, who frame it as a way to speed safe access to lifesaving blood components and reduce red tape for qualified centers.
• Likely supporters: blood centers and hospitals that rely on timely platelet and plasma supplies, citing faster deployment of apheresis devices and new sites.

Who’s Against It

• Potential critics: patient‑safety advocates or watchdog groups concerned that any expedited timeline could pressure thorough review processes.
• Skeptics of narrowing FDA discretion who may argue that site‑specific variation and staffing practices warrant more than a 30‑day default window.

What’s Next

As of October 17, 2025, the bill has been introduced and referred to the House Energy and Commerce Committee. Next steps typically include subcommittee review, possible amendments (“markup”), and committee votes before any potential House floor action; it would then need to pass the Senate and be signed by the President to become law.